T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

LEXINGTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market.

T2 Biosystems Regains Compliance with Nasdaq's Market Value of Listed Securities Requirement

In 2014, Massachusetts-based T2 Biosystems (NASDAQ: TTOO ) went public at $11 per share. Expectations were high for the young startup.

Is TTOO Stock Really Worth $5? Or Just 5 Cents?

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Philip Trip Taylor - Gilmartin Group John Sperzel - President, CEO & Chairman John Sprague - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Greetings. Welcome to T2 Biosystems, Inc. Second Quarter 2023 Earnings Conference Call.

T2 Biosystems, Inc. (TTOO) Q2 2023 Earnings Call Transcript

Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders and received second largest sepsis driven T2Dx® Instrument order

T2 Biosystems Announces Second Quarter 2023 Financial Results

T2 Biosystems (NASDAQ: TTOO ) stock is rallying hard on Thursday, with shares up more than 60% so far in the session. At the session high, TTOO stock was up about 85%.

5 Investors Betting on T2 Biosystems (TTOO) Stock Now

The good news for T2 Biosystems (NASDAQ: TTOO ), and its investors just keeps coming. Earlier this week, the diagnostic testing company received an extension to regain Nasdaq compliance.

GSA Partners Is Betting Big on T2 Biosystems (TTOO) Stock

T2 Biosystems (NASDAQ: TTOO ) stock has been rallying this week after investors learned that the Nasdaq exchange had granted it an extension to regain compliance with two of the exchange's rules. Specifically, the exchange gave the company additional time to meet its requirements by raising its share price above $1 and increasing its market capitalization “to at least $35 million for 10 straight trading days.

TTOO Stock Alert: Is T2 Biosystems the Next Meme Stock?

T2 Biosystems (NASDAQ: TTOO ) stock is enjoying a strong day in the markets on news that it has received an extension to regain Nasdaq compliance, potentially allowing the company to potentially avoid delisting. What's up with TTOO stock today?

TTOO Stock Alert: T2 Biosystems Jumps on Nasdaq Extension

Aurora Cannabis

Faraday Future Intelligent Electric

Canoo

If you're looking for penny stocks to buy right now, you're not alone. The volatility in the stock market today has brought back the risk-on sentiment.

Penny Stocks To Buy Now? 4 Under $1 To Watch This Week

LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2023, to evidence compliance with Nasdaq's minimum bid price and market value of listed securities (“MVLS”) requirements, as set forth in Nasdaq Listing Rules 5550(a)(2) and (b)(2) (the “Rules”).

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements

Bionano Genomics

Brenmiller Energy Ltd

Senseonics Holdings

Soluna Holdings, Inc.

Today's penny stock market is brimming with high-volatility stocks. That especially relates to those that fall into the category of the cheapest penny stocks.

Best Penny Stocks To Buy Now? 6 Under $1 To Watch Now

LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2023 after market close Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Second Quarter 2023 Financial Results on August 7, 2023

LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company's Candida auris (C. auris) direct-from-blood molecular diagnostic test.

T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

G Medical Innovations Holdings Ltd

Inpixon

Moatable Inc

The9 Ltd. Sponsored

Gaucho Group Holdings

Much like baseball, the investing game yields success through mitigated failure, which brings us to the topic of doomed stocks to avoid. No matter who you are, you will never achieve a perfect lifetime record in the capital market.

7 Doomed Stocks Destined for Disaster

Received record quarterly sepsis test panel orders and strengthened balance sheet Received record quarterly sepsis test panel orders and strengthened balance sheet

T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results

LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.

T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity

LEXINGTON, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced a collaborative relationship with Vanderbilt University Medical Center's (VUMC) Learning Healthcare System (LHS) Platform, which unites clinical research and clinical operations to evaluate and implement new approaches to care that can improve the health of patients and the community. Through this collaboration, VUMC will implement and evaluate the FDA-cleared T2Bacteria® Panel in a clinical setting and conduct a prospective study to assess the impact of the direct-from-blood T2Bacteria Panel to improve antibiotic usage and clinical interventions for patients with a bloodstream infection.

T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use

T2 Biosystems (NASDAQ: TTOO ) stock is rising higher on Tuesday after the company revealed its submission for a Breakthrough Device Designation for its Candida auris test. The company has submitted its application for its Candida auris test to the Food and Drug Administration (FDA).

Why Is T2 Biosystems (TTOO) Stock Up 17% Today?

Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems (NASDAQ: TTOO ) stock is rising higher on Thursday after the company announced a new sale of instruments in Poland. According to a press release, this sale covers a multi-year deal for its T2Dx Instruments and sepsis test panels.

Why Is T2 Biosystems (TTOO) Stock Up 29% Today?

Ideanomics Inc

As the financial world constantly evolves, savvy investors are always seeking dynamic strategies to diversify their portfolio. A promising avenue that has gained considerable attention in 2023 is the realm of penny stocks.

Are Penny Stocks Worth Buying? 3 Reasons to Consider

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-driven T2Dx® Instruments in Company history.

T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Philip Taylor - Gilmartin Group John Sperzel - President, CEO & Chairman John Sprague - CFO Brett Giffin - Chief Commercial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Benjamin Haynor - Alliance Global Partners Operator Greetings. Welcome to the T2 Biosystems, Inc. First Quarter 2023 Earnings Conference Call.

T2 Biosystems, Inc. (TTOO) Q1 2023 Earnings Call Transcript

Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives

T2 Biosystems Announces First Quarter 2023 Financial Results

LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced it has initiated a process to explore a range of strategic alternatives focused on maximizing value. To support the strategic process, the Company has initiated a restructuring plan which includes a reduction in force.

News for T2 Biosystems Stock (TTOO)